AstraZeneca Plc’s Covid-19 vaccine study remains paused in the U.S. pending a regulatory review of an incident in which a U.K. study participant became ill, federal officials said.
AstraZeneca’s U.S. Trial Remains on Hold Pending FDA Review
More Stories
Record Korean Cases; Trader’s Guide to Rollout: Virus Update
California Hits Record; Trader’s Guide to Rollout: Virus Update
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push